Remove Communication Remove Diabetes Remove Information
article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

Diabetes 101
article thumbnail

Prescribing Success: Dr. Linda Gutierrez-Miller’s Journey to Impactful Clinical Pharmacy and Inspiring Resilience!

Pharmacy Is Right For Me

Additionally, she holds the title of Certified Diabetes Care and Education Specialist (CDCES). She says, “With over 80 different languages spoken at my clinic, I worry that information gets lost in translation. Her professional journey demonstrates the versatility inherent in a pharmacy career. About Clinical Pharmacists.

Diabetes 306
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Reach 35 New Countries and Improve Diabetes Care Communication: Viseven Collaborations

Viseven

This company specializes in biopharmaceuticals, diabetes care, obesity care, and other severe chronic diseases. The partnership aims to redesign healthcare professionals’ access and use of critical information about diabetes care. Interested in building your own Digital Content Factory? Let us know!

article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). A Phase I/II study of VCTX211 has been commenced and is currently ongoing. It originated under the partnership of CRISPR Therapeutics and ViaCyte.

article thumbnail

Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes

pharmaphorum

In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Collaborating to prevent diabetes. How can we get that message into communities? Digital tools.

Diabetes 111
article thumbnail

Lilly preps for rollout of its connected diabetes system

pharmaphorum

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular disease and nerve damage affecting the eyes and extremities.

article thumbnail

OPDP Issues First Regulatory Action Letter of 2022

Eye on FDA

According to the letter, the agency noted first of all that the video that was part of the Instagram post stated that Trulicity could “lower A1C along with diet and exercise” but that the Medication Guide specifically states that the drug is used for people with type 2 diabetes. So why did OPDP act upon this Instagram post?